GlassScriptPhysician profile
Wenhui Zhu
NPI 1306022066
$3,702.04
in general payments reported to CMS, 2019-2025
39 companies · $745 in 2025
The $745 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $466 · 2021: $323 · 2022: $343 · 2023: $868 · 2024: $649 · 2025: $745.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,177 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,176.78 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $352.56 | 2021-2025 | Pomalyst, Reblozyl, Opdualag |
| Pfizer INC. | $317.36 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $296.11 | 2019-2025 | Opdivo, Krazati, Opdualag |
| Eisai INC. | $230.14 | 2022-2025 | |
| Amgen INC. | $220.88 | 2019-2022 | |
| Daiichi Sankyo INC. | $186.37 | 2023-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $174.08 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $156.96 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $152.85 | 2019-2023 | Tagrisso, Lynparza |
| Gilead Sciences, INC. | $147.71 | 2023-2025 | Trodelvy |
| Regeneron Healthcare Solutions, INC. | $143.05 | 2021-2025 | Libtayo |
| Abbvie INC. | $135.73 | 2019-2025 | |
| Seagen INC. | $134.00 | 2023 | Tukysa |
| Lilly USA, LLC | $86.65 | 2023-2025 | Verzenio, Jaypirca, Retevmo |
| Glaxosmithkline, LLC. | $82.62 | 2021-2025 | Jemperli, Zejula |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wenhui Zhu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.